Accolade, Inc.

ACCD

US00437E1029

Healthcare Facilities & Services

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-24 pm EDT			5-day change	1st Jan Change
9.4 ^USD	+0.53%		+8.05%	-21.73%

Apr. 22	Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating	MT
Mar. 19	Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President	CI

Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 3000 Value Index

June 25, 2021 at 12:00 am EDT

Latest news about Accolade, Inc.

Stifel Adjusts Accolade's Price Target to $13 From $15, Keeps Buy Rating	Apr. 22	MT
Accolade, Inc. Promotes Kelsi McDonald Harris to Chief People Officer and Senior Vice President	Mar. 19	CI
Transcript : Accolade, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-13-2024 01:35 PM	Mar. 13
Leerink Partners Initiates Accolade at Outperform Rating With $16 Price Target	Feb. 26	MT
Accolade Insider Sold Shares Worth $1,554,504, According to a Recent SEC Filing	Jan. 12	MT
Transcript : Accolade, Inc. Presents at J.P. Morgan 42nd Annual Healthcare Conference 2024, Jan-11-2024 07:30 AM	Jan. 11
Accolade Shares Surge After Raymond James Upgrade, Fiscal Q3 Results	Jan. 09	MT
Raymond James Adjusts Accolade's Price Target to $16 From $12, Keeps Outperform Rating	Jan. 09	MT
Accolade Fiscal Q3 Loss Halves, Sales Jump; Issues Guidance	Jan. 08	MT
Transcript : Accolade, Inc., Q3 2024 Earnings Call, Jan 08, 2024	Jan. 08
Accolade, Inc. Provides Earnings Guidance for the Fourth Quarter and Year Ending February 29, 2024 and Year Ending February 28, 2025	Jan. 08	CI
Accolade Guides For Q4 Revenue of $121.5-$125.5 Million, vs CIQ Analyst Consensus of $126.4 Million	Jan. 08	MT
Accolade, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended November 30, 2023	Jan. 08	CI
North American Morning Briefing : Boeing Drags Down Dow Futures	Jan. 08	DJ
Stifel Cuts Accolade's Price Target to $15 From $17, Keeps Buy Rating	Jan. 04	MT
Piper Sandler Adjusts Accolade's Price Target to $12 From $15, Maintains Overweight Rating	Nov. 22	MT
Accolade to Repurchase $76.5 Million of Outstanding Debt	Nov. 16	MT
U.S. employers covering weight-loss drugs could nearly double in 2024 - survey	23-10-09	RE
Canaccord Genuity Adjusts Accolade Price Target to $17 From $18, Maintains Buy Rating	23-10-05	MT
Truist Securities Adjusts Price Target on Accolade to $15 From $17, Keeps Buy Rating	23-10-05	MT
Raymond James Adjusts Price Target on Accolade to $12 From $15, Keeps Outperform Rating	23-10-05	MT
Accolade Reports Narrowing Net Loss in Fiscal Q2 as Sales Increase	23-10-05	MT
Accolade, Inc. Provides Earnings Guidance for the Third Quarter and Full Fiscal Year 2024	23-10-04	CI
Transcript : Accolade, Inc., Q2 2024 Earnings Call, Oct 04, 2023	23-10-04
Accolade, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended August 31, 2023	23-10-04	CI

Accolade, Inc. provides personalized, technology-enabled solutions that help people understand, navigate, and utilize the healthcare system and their workplace benefits. Its customers are primarily employers that deploy Accolade solutions in order to provide employees and their families with a single place to turn for their health, healthcare, and benefits needs. It also offers medical opinion services to commercial customers and virtual primary care and mental health support. Its platform, True Health Engine, combines open, cloud-based intelligent technology with multimodal support from a team of empathetic and knowledgeable Accolade Health Assistants and clinicians, including registered nurses, physician medical directors, pharmacists, behavioral health specialists, womenâs health specialists, case management specialists, expert medical opinion providers, and virtual primary care physicians. Its offerings include Accolade Expert MD, Accolade Care, Plus and Connect and Accolade One.

Sector

Healthcare Facilities & Services

Calendar

2024-04-24 - Q4 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Accolade, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

9.4 USD

Average target price

14.8 USD

Spread / Average Target

+57.45%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Healthcare Facilities & Services

	1st Jan change	Capi.
ACCOLADE, INC.	-21.73%	728M
CVS HEALTH CORPORATION	-14.17%	85.42B
HCA HEALTHCARE, INC.	+17.86%	84.38B
DR. SULAIMAN AL HABIB MEDICAL SERVICES GROUP COMPANY	+10.92%	29.39B
LABORATORY CORPORATION OF AMERICA HOLDINGS	-8.51%	17.49B
FRESENIUS SE & CO. KGAA	-2.32%	16.44B
QUEST DIAGNOSTICS INCORPORATED	-0.24%	15.28B
EUROFINS SCIENTIFIC SE	-2.51%	11.71B
FRESENIUS MEDICAL CARE AG	+1.08%	12.22B
PURE HEALTH HOLDING	-31.40%	11.98B

Other Healthcare Facilities & Services

Accolade, Inc.

Equities

ACCD

US00437E1029

Healthcare Facilities & Services

Accolade, Inc.(NasdaqGS:ACCD) dropped from Russell 3000 Value Index

Latest news about Accolade, Inc.

Chart Accolade, Inc.

Company Profile

Income Statement Evolution

Ratings for Accolade, Inc.

Analysts' Consensus

EPS Revisions

Quarterly earnings - Rate of surprise

Sector Other Healthcare Facilities & Services